Tag Archives: IPAR

Hot Warren Buffett Stocks To Buy Right Now

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-806d0418ba4a44129f466489520d621a&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/806d0418ba4a44129f466489520d621a/960×0.jpg?fit=scale&q; data-height=&q;699&q; data-width=&q;960&q;&g;

Among the many gems in Warren Buffett&s;s &l;a href=&q;http://www.berkshirehathaway.com/letters/letters.html&q; target=&q;_blank&q;&g;recent letter&l;/a&g; is another warning about the perils of debt. Whether you&s;re a student, a CFO, an entrepreneur or a retiree, it&s;s worth listening. Buffett has written many times with pith....More>>>

Best Casino Stocks To Own For 2019

Third Point, the activist fund run by Dan Loeb, exited a series of high-profile positions during the first quarter, including stakes in Honeywell International Inc., Time Warner Inc., MGM Resorts International and U.S. mall owner Macerich Co.

The New York-based hedge fund also added a position in Wynn Resorts Ltd., according to a regulatory filing Tuesday. The Las Vegas-based casino company’s co-founder and chief executive officer, Steve Wynn, resigned in February amid allegations of sexual harassment. Wynn Resorts made a surprise announcement Monday that two directors were resigning,....More>>>

Top 10 Stocks To Buy For 2019

Yesterday, our Under the Radar Movers newsletter suggested small cap functional ingredient stock Neptune Technologies & Bioressources (NASDAQ: NEPT) as a long/bullish trade:

“As for Neptune Technologies and Biosciences, again, this is just another short-term volatility play. We won’t be in it very long. We do want in though, as when volume starts to pour in, it’s been great for the stock. We just want to get in at a bottom, right in front of a very familiar swing.”

Our Under the Radar Movers newsletter would have a further discussion about Neptune’s technical....More>>>

Best Value Stocks To Watch For 2019

Shares of Sarepta Therapeutics (SRPT) have gotten crushed today after the FDA offered a negative take on Sarepta’s Duchenne muscular dystrophy drug. In fact, Leerink’s Joseph Schwartz and team contend that Sarepta’s “dystrophin argument strongly challenged and largely invalidated by the FDA.” They explain:

Andrew Harnik/Associated Press

The updated FDA review is even more negative on the historical control data. 4-yr. clinical effectiveness data submitted in January at the time was considered as major amendment to eteplirsen NDA that had resulted in....More>>>

Top Medical Stocks To Invest In Right Now

Scott Kicks Off Battle Over Senate Tax Bill Life Provisions

What Brighthouse Told Investors About Distribution

Senate Republicans to Add ACA Mandate Fight to Tax Fight

Cigna Health and Life Insurance Co. was fined $2 million on Tuesday by New York’s Department of Financial Services in connection with allegations that the company violated state insurance laws.

The department found, after an investigation, that Cigna sold stop-loss insurance to small employers.

Employers that offer self-insured health plans use stop-loss to protect themselves against big....More>>>